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The intrinsic pathway of coagulation is initiated when zymogcn factor VII binds to its cell surfxe receptor tissue factor to form a catalytic binary 
complex. Both the activation of factor VII to factor Vlla and the expression ofserine protuase activity of factor VlIa are dependent on factor VII 
binding to tissue factor lipoprotein. To better understand the molecular basis of these rate-limiting events, the intcractian of zymogcn factor VII 
and tissue factor was investigated using as probes both a murine monoclonal antibody and a monospecific rabbit antiserum to human factor VII. 
To measure fnctor Vllti functional activity, a two-stage chromogenic assay was used; an nsstly which measures the factor Xa generated by the 
activation of factor VII to factor Vlla. Purilicd immunoglobulin from murine moncclonal antibody 231-7. which was shown to bc reactive with 
amino acid residues 5l-SE of the first epidermal growth factor-like (EGF) domain of human factor VII, inhibited the activation of factor VII to 
factor VIla in a dose-dependent manner. The mechanism of this inhibition was demonstrated using a novel solid-phase ELISA which quantitatively 
measured the binding of purified factor VII zymogen to tissue factor adsorbed onto microtitcr wells. Thus, the binding of factor VII rymogcn to 
immobilized tissue factor was inhibited by antibody 231-7, again in a dose-dcpcndent manner, Similar results were obtained using a monospecific 
rabbit antiserum to human factor VII which also reacted with the fl-galactosidase fusion proteins containing amino acid residues 51-88 (exon 4) 
of human factor VII. WC conclude therefore that the CXOII 4.encoded amino acids of the first EGF domain of human factor VII constitute an essential 
domain participating in the binding of factor VII to tissue factor. 
Blood coagulation; Extrinsic pathway; Human fuctor VII, tissue factor 
1 a INTRODUCTICN 
The initiation of blood coagulation is generally 
thought of as occurring either by the intrinsic or ex- 
trinsic pathways, but the precise series of molecular 
events initiating either pathway have not been com- 
pletely defined [l]. Activation of factor VII zymogen 
occurs on the surface of cells expressing the lipoprotein 
receptor tissue factor, which is dependent on the pres- 
ence of both Ca?’ and activated factor Xa [2,3]. Struc- 
tural integrity of the y-carboxylated glutamic acid (Gla) 
residues, the calcium-binding Gla domain situated at 
the amino terminus of factor VII, has been shown to be 
a prerequisite for factor W-tissue factor interaction 
[4]. However, other vitamin K-dependent coagulation 
proteins including prothrombin, factor IX, factor X, 
protein C, protein S and protein 2 also contain Gla 
domains which are highly similar in amino acid se- 
quence to fActor VII [5-71 yet do not bind tissue factor. 
In an attempt o further define this interaction, the bind- 
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ing of factor VII to tissue factor was therefore xamined 
using both monoclonal and monospecific polyclonal 
antibodies to factor VII. Our results provide evidence 
that the first EGF domain of factor VII is essential for 
the binding of tissue factor to factor VII and thus is 
critical for the initiation of extrinsic oagulation. These 
results were presented in part at the annual meeting of 
the American Society of Hematology [S]. 
2. MATERIALS AND METHODS 
Muman fuctor VII, factor Vlla, and rabbit polyclonal anti-human 
factor VII antiserum were purchased from Diagnostica Stago 
(Wcllmark Diagnostics, Guclph, ONT). Human factor VII was also 
purified in our laboratory from factor VII concentrate (generously 
provided by Immune AG, Vienna, Austria) on a Sepharose 4B immu= 
noabsorbent column containing covalently attached immunoglobulin 
G (IgG) from murinc monoclonal antibody 231-7 to factor VII [9], For 
some experiments, human factor VII prepared by Enzyme Research 
Laboralories Inc. (Southbend, IN) was used. Thromborel S (tissue 
factor from human plucenta) was obtained from Bchring Diagnostics 
(Hoechst Canada Inc., Montreal, QUE). S-2222 (Nabenzoyl-L-iso. 
leucyl-~-gIutamyl-glycyl-~-arginine-~nitroanilide),  chromogenic sub- 
strate for factor Xa, was ob\ained from Kebivilrum (Helena hbo- 
ratories, Mississaugu, ONT). Recombinant issue factor apoprotein 
was a generous gift of Gcnentech Inc., (San Francisco, CA) and was 
reconstituted iruo phosphutidylcholinc-phosphatidyl scrinc vesicles 
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(40:60 by wt.) as described by Rao and Rapaport [IO]. Factor X was 
purified from normal human plasma as previously described [I I]. 
Russell’s Viper Venom (RVV) was obtained from Enzyme Research 
Laboratories, Inc. Isopropyl-p-~thiogalactopyranosidc (IPTG), p- 
aminobcnzyl-I-thio-/l-D-galaclopyranoside (ABTG)-agarosc, Twccn- 
20, discdium-p-nitrophcnyl phosphate and bovine serum albumin 
(BSA), fraction V, were from Sigma Chemical Company (St. Louis, 
MO). Goal anti-rabbit IgG and goat anti-mouse IgG conjugated with 
alkaline phosphatase was from Jackson lmmuno Rcscarch Labo- 
ralorics (West Grove, PA). ELISA assays were performed in 96well 
flat bottomed well polystyrene microtitre plates (Immulon II, Dy- 
natecb Laboratories, Inc., Chantilly, VA). All other chemicals were 
analytical grade reagents. 
2a2. Mrrpping 01 rhc MAb [231-T/ birrding eppiropc 011 jkvor VII 
Construction of a 200-300 bust pair (bp) factor VII cDNA library 
in lambda gtl 1 was performed exactly as previously described [12]. 
Full-length factor VlI cDNA in plasmid pDx [$I 31 was a gift from 
Dr. Earl Davic (Seattle, Washington). Approximately 1x IO5 bacte- 
riophage from the factor VII Agtl I cDNA library was plated on E. 
co/i 109O~)y(-) (Promega Biotec) and fusion proteins were induced with 
IPTG [12]. Twenty strongly positive MAb [231-71 immunorcactive 
plaques were idenlified on IO scparalc discs. Eighteen of the twenly 
initial phage population identified were successfully plaque-purified. 
DNA was isolated from each of the phage populations. the putative 
factor VII cDNA inserts were released from the vector DNA by 
digestion with EcoRI, the DNA was end-labelled with [a-“P]dATP 
and sized by electrophoresis on a 5% polyacrylamide gel [14]. The 
seven shortest putative factor VII cDNA inserts were subcloned into 
the EcuRI site of bactcriophagc Ml3mpl8 and the DNA sequence of 
the inserts determined as described previously [12]. Each insert con- 
tained the DNA coding for a region of factor VII. 
2.3. Cl~rorrtogcnic assay Jar factor VII 
Factor VII activation or factor VIIa enzyme activity were assayed 
using minor modifications of n two-step coupled amidolytic assay, 
employing the chromo8cnic substrate S-2222 [IS]. The buffer used to 
prepare all reagents was 0.05 M Tris, pH 8.3, containing 0. I5 M NaCl 
and I mdml BSA. Thromborel S (tissue factor) was reconstituted in 
Ha0 as suggested by the manufacturer and diluted 2.5 times in buffer 
just before USC. In the lirst step of the aS$dy, the reaction mixlurc 
contained tissue fuctor (50 PI), factor VII (S&9 ng/ml) or factor Vlla 
(22 @ml). calcium chloride (5.5 mM) and purified factor X (4ydml) 
in a final volume of 0.225 ml. Conditions were standardized so that 
the amount of factor Xa generated depended upon the concentration 
of factor VII (or factor Vlla) in the reaction mixture. After incubation 
for 3 min at 37”C, the reaction was stopped by the addition of25 ,uI 
of 0.3 M Na.EDTA and cooled on ice. In the second step, the gcn- 
eraled factor Xa activity was measured by adding a subsample (62.5 
,ul) of the incubation mixture to 437.5 ~1 of0.2 mM S-2222 in 0.05 M 
TBS, pH 8.3. The initial rate ofclcavagc ofS-2222 was determined by 
following the AAdos nm/min in a Delta 1000 Spectrophotometer 
(Smith- Kline Instruments Inc., Sunnyvale, CA). 
2.4. AnriOorly itrhibitiott oJjktcrr Vii activation 
Tbc chromogenic assay was modilicd slightly to study the efT’cct of
anti-human factor YII antibodies. In the first step, factor VII (or 
factor VlIa), calcium, and varying amounts of anti-factor VII anti- 
body were incubated for I h at room temperature. Purified factor X 
was then added followed by tissue factor and the reaction allowed to 
proceed for 3 min at 37OC. Subsequent operations were as described 
above. 
A solid-phase nzyme-linked immunoadsorbent assay (ELISA) to 
measure binding of factor VII to tissue factor was developed. Tissue 
factor (TF) was reconstituted in antigen coating buffer (0.05 M 
Na+ZO-NaHCO,, pH 9.6) and 100 ,uI was coated onto wells of Im- 
mulon II plastic microlitre plates overnight at 4°C. The plates were 
subsquently wushed lhree times with TBS-T bufI-cr (IO mM Tris, pH 
8.0,0.9% NaCI, 0.05% (v/v) Tween-20.5 mM Ca”) and non-specific 
binding sites were blocked by incubation with 0.35 ml dTBS-T buffer, 
containing 1 mdml BSA for 2 h at 20°C. Human factor VII was 
incubated alone or in the presence of various Eoncentrations of factor 
VII antibody in TBS-T buffer containing 1 mdml BSA for 2 h at CC. 
Triplicate IO0 ~1 aliquots were then added to microtitre plate wells 
coated with tissue factor and incubated for 2 h at 20°C. The amount 
of factor VII bound to the tissue factor-coated wells was determined 
by the sequential ddition and incubation for I h at ZO’C each of 100 
yl of rabbit polyclonal antisera to human factor VII (1:2000 dilution) 
and alkaline phosphate-conjugated goat anti-rabbit IgG (I:5000 dilu- 
tion). Microtiter plales were washed 3-5x after the addition of each 
of the above reagents Finally, 100 yl of a 1 mdml solution ofp- 
nilropbcnyl phosphate in substrate buli’er (10% dicthanolaminc. 0 5 
mM M&I?, 0.02% NaN,. pH 9.8) was added to wells and incubated 
for I h at 20°C. Absorbance at 405 urn was dctcnnined in an au- 
tomated ELISA plate reader. The amount of free factor VII in the 
antibody-containing samples was expressed as a percent of control. 
26. Isolu!ion of P-g&ctosidase jision pro&s cor~tainittg Aunrarr 
Juctor VII 
Lysogens of Agtl I -fnclor VII recombinant bacteriophage were 
grown in culture and fusion protein production induced by IPTG as 
previously described [ 12,161. Cells were bat-vested bycentrifugation 
anda-galactosidase f&on proteinsextracted and isoiatcd as dcscribcd 
[ 16,171. Final puriftcation of the ~@tctosidase fusion proteins was 
achieved by affinity chromatography onan ABTG-agarose column as 
described [ 17, IS]. Purity of the eluled fusion protein was greater than 
95% as analyscd by SDS-polyacrylamide g l clcctrophoresis. Two 
p-galactosidasc fusion proteins containing human. factor VII amino 
acids 25-88 (fusion protein S-9) and factor VII amino acids 46-107 
(fusion protein 9-2) were thus purilied. Both proteins had in common 
a regiuu of sequence ncompassing the first EGF domain of human 
factor VII. Control &alactosidaae ncoded by wild-type 1glll was 
preparcz and purified in a similar manner, The immunogtnicily of the 
two j-galactosidase fusion proteins, containing portions of human 
factor VII, was verilied by solid-phase ELISA using both the murine 
monoclonal antibody 231-7 and the rabbit polyclonal antiserum to 
human factor VII as described above. 
3. RESULTS 
3.1. SpeciJciry of anti-j&/or VII antibodies 
As shown in Table I, the two shortest factor VII 
inserts contained in phage clones 9 (amino acid residues 
25-88) and 11 (amino acid residues 51-114) limit the 
Table I 
DNA sequence analysis of factor VII recombinant bacteriophage 
Pbage clone Factor VII 
amino acids encoded 
2 43-105 
3 43-l I3 
8 46-107 
9” 25-88 
II* 51-I 14 
18 36-95 
I9 21-89 
Consensus equence 51-88 
*These two clones define the maximum limits of the cpitope re- 
cognizcd by monoclonal antibody 23 l-7. 
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Fig. I. Effect of MAb 231-7 IgG (0) and control mouse immunoglo~ 
bulin (A) on the activation of factor VII as measured by chromogenic 
assay. Conirol rcuction mixture without any antibody is taken to give 
100% activation of factor VII and values for samples containing anti- 
body are expressed as a percentage ofconlrol. Error bars are S,E.M. 
of triplicate dcicrminations. 
MAb 231-7 binding epitope to amino acid residues 51- 
88 of human factor VII. This epitope is part of the first 
EGF domain of factor VII. The MAb 231-7 belonged 
to the IgG, subclass and its specificity was confirmed by 
ELlSA experiments using purified &galactosidase fu- 
sion proteins 8-9 and 9-2 containing the first EGF 
domain amino acid residues 46-W Similarly, the mo- 
nospecific polyclonal rabbit antiserum to factor VII 
also strongly reacted with the two fusion proteins, indi- 
cating the presence of antibodies against he first EGF 
domain of factor VII (data not shown). 
3.2. Antibody-mediated inhibitinn of fuctor VII activa- 
tion 
Initial experiments were performed to determine 
whether antibodies to factor VII might be useful in 
mapping the tissue factor binding domain(s). The effect 
of varying doses of MAb 23 I-7 on f’actor VII activation 
was studied in a conventional two-stage chromogenic 
assay system. As seen from Fig. 1, MAb 231-7 markedly 
inhibited factor VII activation. The dose-response curve 
was sigmoidal suggesting that the inhibition observed 
was co-operative in nature. Half-maximal inhibition oc- 
curred at a 44:l molar ratio of antibody to factor VII. 
Control mouse immunoglobulin of the same IgG sub- 
class had no effect on activation of factor VII. Similarly, 
MAb 231-7 had no effect on either activation of factor 
X to factor Xa by RVV or the cleavage of the chromo- 
genic substrate S-2222 by purified factor Xa (data not 
shown). These results indicated that the first EGF 
domain of factor VII is involved in the activation of 
factor VII zymogen to factor VIIa. 
Similar results were obtained using the rabbit poly- 
clonal antiserum monospecific for human factor VII. 
Half maximal inhibition of factor VII activation by 
rabbit polyclonal antibody occurred at l:lO,OOO dilu- 
tion of antisera. Normal rabbit serum had no effect on 
the activation of factor VIl. Neither RVV activation of 
factor X to Xa nor purified factor Xa activity was af- 
fected by the presence of rabbit antibodies (data not 
shown). 
3.3. Antibody-mediated inhibition of the binding of tissue 
factor to factor VII 
In order to test the hypothesis that the above antibod- 
ies to factor VII were inhibiting the interaction of factor 
VII with its essential co-factor tissue factor, we devised 
a simple, solid-phase ELISA to measure factor VII 
binding to immobilized tissue factor. The assay was 
shown to be linear over the range of 3-20 ng factor VII. 
However, when preincubated with MAb 231-7, the 
binding of factor VII to tissue factor decreased progres- 
sively as the molar ratio of MAb 231.7 1gG to factor VII 
increased from 1:l to 1OO:l (Fig. 2). Half-maximal in- 
hibition of binding of factor VII to immobilized tissue 
factor occurred at about 1O:l molar ratio of IgG to 
factor VII. Control mouse immunoglobulin of the same 
IgG subclass had no effect in the concentration range 
tested. Similar results were obtained with rabbit poly- 
clonal serum monospecific for factor VII, i.e. after 
preincubation of the antiserum with factor VII the bind- 
ing of factor VII to tissue factor decreased progressively 
as the antiserum dilution was varied from 1:5,000 to 
1:400. Half-maximal inhibition of binding of factor VII 
0 
CON 1:l 6:1 25:l so:1 1OO:l 
291-7 I2a: FACTOR VII 
MOLAR RATIO 
Fig. 2. Effect of MAb 331-7 I@ on the binding of factor VII to 
immobilized tissue facto:. Control reaction mixlure without any anti- 
body is taken to give 100% binding of factor VII to TF and values ror 
samples containing antibody are cxprcssed as a percentage ofcontrol. 
Erros bars arc S.E.M. of triplicate determinations, Control mouse 
immunoglobulin did not have any effect on factor VII binding to TF. 
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to immobilized tissue factor by rabbit antiserum oc- 
curred at I: 1,000 dilution of the serum (data not 
shown). Normal rabbit serum had no significant effect 
in the assay system. When purified relipidated recom- 
binant tissue factor was substituted for crude tissue 
factor in the assay system, identical results were ob- 
tained (data not shown). 
3.4. Purijied tissue fuctor blocks ittteractiott of MAb 
231-7 attdJucror VII 
In an ELKA-type assay, relipidated recombinant tis- 
sue factor was found to block the binding of MAb 231-7 
to purified factor VII immogilized on a microtiter plate 
(data not shown). The inhibition of MAb 231-7 binding 
by TF was dose-dependent and reached a steady level 
of about 40% inhibition at 25 ng TF. In a converse of 
this experiment, MAb 231-7 failed completely to bind 
factor VII, which was preincubated and bound to 
purified TF immobilized on a microtiter plate. These 
experiments further support the concept that both TF 
and MAb 231-7 compete for the same binding site on 
factor VII. 
4. DISCUSSION 
A number of investigators have recently addressed 
the issue of the tissue-factor-binding domain(s) of factor 
VII. It has been known for a long time that y-carboxyla- 
tion of the glutamic acid residues of the vitamin K- 
dependent coagulation factors is a necessary feature for 
the manifestation of their biological activity [19]. Mo- 
reover, there is now direct evidence indicating that the 
Gla domain of factor VII is essential for interaction 
with tissue factor [4], In addition, the two EGF domains 
of factor VII have been implicated recently as compris- 
ing an important issue factor recognition determinant 
on factor VII [20]. These studies were based on observa- 
tions with chimeric proteins composed of domains from 
human factor VII linked to human factor IX. Only 
chimeric proteins containing both EGF domains of 
factor VII bound tissue factor [20]. Other investigators, 
using synthetic pcptides corresponding to various 
regions of human factor VII, reported 2 regions to be 
of importance for tissue factor binding; those compris- 
ing amino acid residues 44-50, and 285-305 [21,22]. In 
the latter report [22], evidence was provided that the 
latter domain was critical for factor X activation. An- 
other group of investigators reported amino acid 
residues 195-206 to be critical for factor Vll binding to 
tissue factor [23]. Thus, the Gla domain, the EGF 
domain, and the heavy chain of human factor VII have 
been implicated in the binding of tissue factor with 
factor VII. It is likely that the Gla-domain interacts with 
the phospholipid moiety of tissue factor while the latter 
two interact with the apoprotein [4,24]. 
Conversely, investigations exploring the recognition 
domains on the tissue factor apoprotein have delineated 
two domains within the extraccllular portion of the tis- 
sue factor molecule that interact with factor VII [24-261. 
Thus, from the available vidence, there appear to be at 
least two interactive domains between human tissue 
factor apoprotein and the human factor VII molecule, 
which facilitate the activation of factor VII by factor 
Xa. For factor Vll it is likely that one of these binding 
domains is contained within the light and the other 
within the heavy chain. With regard to the domain 
within the light chain, the domains comprising the two 
EGF structures have been implicated [8,20]. The 
evidence provided in this communication pinpoints this 
tissue factor binding region to the first EGF domain. 
Direct evidence that the first EGF domain participates 
in tissue factor binding has recently been provided by 
the natural mutation factor VII-Charlotte [27,28]. This 
mutant factor VII has an Arg’:‘“+Gln mutation within 
the first EGF domain [27,28]. Finally, we have shown 
recently that both plasma-derived and recombinant 
factor VII-Charlotte do not bind to tissue factor (Migh, 
Chaing, Sridhara, Clarke and Blajchman, unpublished 
results). 
In summary, all of available vidence provided in this 
report points to the first EGF domain of factor VII to 
be a critical tissue factor binding domain on human 
factor VII. Studies are required to further delineate this 
and other critical binding domains for this important 
interaction. 
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